Patient Square Capital LP Invests $4.49 Million in Pharvaris (NASDAQ:PHVS)

Patient Square Capital LP bought a new position in Pharvaris (NASDAQ:PHVS) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 242,341 shares of the company’s stock, valued at approximately $4,488,000. Pharvaris accounts for approximately 1.7% of Patient Square Capital LP’s investment portfolio, making the stock its 7th largest position.

Several other large investors also recently modified their holdings of the stock. HighVista Strategies LLC boosted its holdings in Pharvaris by 35.9% in the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after acquiring an additional 6,018 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pharvaris during the third quarter worth approximately $906,000. Sofinnova Investments Inc. grew its position in Pharvaris by 2.9% in the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock valued at $11,309,000 after purchasing an additional 16,862 shares during the period. Deerfield Management Company L.P. Series C increased its stake in Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after purchasing an additional 335,687 shares in the last quarter. Finally, Novo Holdings A S raised its holdings in Pharvaris by 47.7% during the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after buying an additional 556,970 shares during the last quarter.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer raised their price target on shares of Pharvaris from $38.00 to $42.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.60.

Pharvaris Stock Up 3.3 %

Shares of PHVS opened at $19.78 on Wednesday. The stock has a 50 day moving average of $21.07 and a 200 day moving average of $19.29. Pharvaris has a 12 month low of $15.37 and a 12 month high of $33.00.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.